DJIA 17,672.60 -141.38 -0.79%
NASDAQ 4,757.88 7.48 0.16%
S&P 500 2,051.82 -11.33 -0.55%
market minute promo

Novo Nordisk (NYSE: NVO)

43.88 -0.37 (-0.84%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NVO $43.88 -0.84%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $44.18
Previous Close $44.25
Daily Range $43.85 - $44.41
52-Week Range $37.21 - $49.11
Market Cap $120.7B
P/E Ratio 0.00
Dividend (Yield) $0.61 (1.4%)
Ex-Dividend Date
Dividend Pay Date
03/21/14
04/02/14
Volume 1,878,180
Average Daily Volume 1,282,626
Current FY EPS $1.58

Sector

Healthcare

Industry

Drugs

Novo Nordisk (NVO) Description

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals. Website: http://www.novonordisk.com/

News & Commentary Rss Feed

State of the Union Address Investing Idea: Precision Medicine

There are plenty of companies developing precision medicine drugs already, and investors would be wise to watch key players.

Novo Nordisk Receives Positive Opinion In Europe On Obesity Treatment

MannKind Corporation on Track for Afrezza Launch

MannKind partner Sanofi is close to launching its inhaled insulin Afrezza, but will doctors prescribe it?

Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst Blog

Three Companies That Should Benefit From a Stronger U.S. Dollar

5 Obesity Stocks Investors Are Watching

Heavy Volume And Pre-Market Movement For Novo Nordisk A/S (NVO)

I Think This Next-Generation Diabetes Drug Offers the Greatest Growth Potential

Three Motley Fool analysts weigh in with the companies they think could benefit from launching next generation diabetes treatments.

Does Sanofi's $50 Million Milestone Payment to MannKind Corp. Matter?

Sanofi has made a $50 million milestone payment to MannKind, but Afrezza's success or failure is far more important to MannKind this year.

Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More

See More NVO News...

NVO's Top Competitors

NVO $43.88 (-0.84%)
Current stock: NVO
JNJ $102.20 (-1.50%)
Current stock: JNJ
NVS $96.87 (0.03%)
Current stock: NVS
RHHBY $35.35 (1.83%)
Current stock: RHHBY